Találati lista | Tudóstér

001-es BibID:	BIBFORM070110
Első szerző:	Altenberger, Johann
Cím:	Levosimendan in acute and advanced heart failure : an appraisal of the clinical database and evaluation of its therapeutic applications / Altenberger J., Gustafsson F., Harjola Veli-Pekka, Karason K., Kindgen-Milles D., Kivikko M., Malfatto G., Papp Z., Parissis J., Pollesello P., Pölzl G., Tschöpe C.
Dátum:	2018
ISSN:	0160-2446
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Journal Of Cardiovascular Pharmacology. - 71 : 3 (2018), p. 129-136. -
További szerzők:	Gustafsson, Finn Harjola, Veli-Pekka Karason, Kristian Kindgen-Milles, D. Kivikko, Matti Malfatto, Gabriella Papp Zoltán (1965-) (kardiológus, élettanász) Parissis, John Pollesello, Piero Pölzl, Gerhard Tschöpe, Carsten
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM076735
Első szerző:	Bouchez, Stefan
Cím:	Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application / S. Bouchez, F. Fedele, G. Giannakoulas, F. Gustafsson, Veli-Pekka Harjola, K. Karason, M. Kivikko, D. von Lewinski, F. Oliva, Z. Papp, J. Parissis, Piero Pollesello, G. Pölzl, C. Tschöpe
Dátum:	2018
ISSN:	0920-3206
Megjegyzések:	Levosimendan, a calcium sensitizer and potassium channel-opener, is widely appreciated by many specialist heart failure practitioners for its effects on systemic and pulmonary hemodynamics and for the relief of symptoms of acute heart failure. The drug's impact on mortality in large randomized controlled trials has been inconsistent or inconclusive but, in contrast to conventional inotropes, there have been no indications of worsened survival and some signals of improved heart failure-related quality of life. For this reason, levosimendan has been proposed as a safer inodilator option than traditional agents in settings, such as advanced heart failure. Positive effects of levosimendan on renal function have also been described. At the HEART FAILURE 2018 congress of the Heart Failure Association of the European Society of Cardiology, safe and effective use levosimendan in acute and advanced heart failure was examined in a series of expert tutorials. The proceedings of those tutorials are summarized in this review, with special reference to advanced heart failure and heart failure with concomitant renal dysfunction. Meta-analysis of clinical trials data is supportive of a renal-protective effect of levosimendan, while physiological observations suggest that this effect is exerted at least in part via organ-specific effects that may include selective vasodilation of glomerular afferent arterioles and increased renal blood flow, with no compromise of renal oxygenation. These lines of evidence require further investigation and their clinical significance needs to be evaluated in specifically designed prospective trials.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Inodilators Inotropes Acute heart failure Advanced heart failure Levosimendan Renal function
Megjelenés:	Cardiovascular Drugs And Therapy. - 32 : 6 (2018), p. 617-624. -
További szerzők:	Fedele, Francesco Giannakoulas, George Gustafsson, Finn Harjola, Veli-Pekka Karason, Kristian Kivikko, Matti von Lewinski, Dirk Oliva, Fabrizio Papp Zoltán (1965-) (kardiológus, élettanász) Parissis, John Pollesello, Piero Pölzl, Gerhard Tschöpe, Carsten
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:

BIBFORM090883

Első szerző:

Papp Zoltán (kardiológus, élettanász)

Cím:

Levosimendan Efficacy and Safety : 20 Years of SIMDAX in Clinical Use / Papp Zoltán, Agostoni Piergiuseppe, Alvarez Julian, Bettex Dominique, Bouchez Stefan, Brito Dulce, Černý Vladimir, Comin-Colet Josep, Crespo-Leiro Marisa G., Delgado Juan F., Édes Istvan, Eremenko Alexander A., Farmakis Dimitrios, Fedele Francesco, Fonseca Cândida, Fruhwald Sonja, Girardis Massimo, Guarracino Fabio, Harjola Veli-Pekka, Heringlake Matthias, Herpain Antoine, Heunks Leo M. A., Husebye Trygve, Ivancan Višnja, Karason Kristjan, Kaul Sundeep, Kivikko Matti, Kubica Janek, Masip Josep, Matskeplishvili Simon, Mebazaa Alexandre, Nieminen Markku S., Oliva Fabrizio, Papp Julius-Gyula, Parissis John, Parkhomenko Alexander, Põder Pentti, Pölzl Gerhard, Reinecke Alexander, Ricksten Sven-Erik, Riha Hynek, Rudiger Alain, Sarapohja Toni, Schwinger Robert H. G., Toller Wolfgang, Tritapepe Luigi, Tschöpe Carsten, Wikström Gerhard, von Lewinski Dirk, Vrtovec Bojan, Pollesello Piero

Dátum:

2020

ISSN:

0160-2446

Megjegyzések:

Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart failure (HF). In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitization and promotes vasodilatation through the opening of adenosine triphosphate-dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the European Union and Latin America. Areas of clinical application have expanded considerably and now include cardiogenic shock, takotsubo cardiomyopathy, advanced HF, right ventricular failure, pulmonary hypertension, cardiac surgery, critical care, and emergency medicine. Levosimendan is currently in active clinical evaluation in the United States. Levosimendan in IV formulation is being used as a research tool in the exploration of a wide range of cardiac and noncardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis. To mark the 20 years since the advent of levosimendan in clinical use, 51 experts from 23 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, the United Kingdom, and Ukraine) contributed to this essay, which evaluates one of the relatively few drugs to have been successfully introduced into the acute HF arena in recent times and charts a possible development trajectory for the next 20 years.
Papp Zoltán (1965-) (kardiológus, élettanász): Levosimendan Efficacy and Safety : 20 years of SIMDAX in Clinical Use

Tárgyszavak:

Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk

Megjelenés:

Journal Of Cardiovascular Pharmacology. - 76 : 1 (2020), p. 4-22. -

További szerzők:

Agostoni, Piergiuseppe Alvarez, Julian Bettex, Dominique Bouchez, Stefan Brito, Dulce Cerny, Vladimir Comin-Colet, Josep Crespo-Leiro, Maria G. Delgado, Juan F. Édes István (1952-) (kardiológus) Eremenko, Alexandr A. Farmakis, Dimitrios Fedele, Francesco Fonseca, Candida Fruhwald, Sonja Girardis, Massimo Guarracino, Fabio Harjola, Veli-Pekka Heringlake, Matthias Herpain, Antoine Heunks, Leo M. A. Husebye, Trygve Ivancan, Visnja Karason, Kristian Kaul, Sundeep Kivikko, Matti Kubica, Janek Masip, Josep Matskeplishvili, Simon Mebazaa, Alexandre Nieminen, Markku S. Oliva, Fabrizio Papp Gy. Julius (Szeged) Parissis, John Parkhomenko, Alexander Põder, Pentti Pölzl, Gerhard Reinecke, Alexander Ricksten, Sven-Erik Riha, Hynek Rudiger, Alain Sarapohja, Toni Schwinger, Robert H. G. Toller, Wolfgang Tritapepe, Luigi Tschöpe, Carsten Wikström, Gerhard von Lewinski, Dirk Vrtovec, Bojan Pollesello, Piero

Internet cím:

Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat

Lásd még:

Egyéb kapcsolat (1)

Borító:

Saját polcon:

001-es BibID:

BIBFORM090869

035-os BibID:

(cikkazonosító)e19

Első szerző:

Papp Zoltán (kardiológus, élettanász)

Cím:

Levosimendan Efficacy and Safety : 20 years of SIMDAX in Clinical Use / Papp Zoltán, Agostoni Piergiuseppe, Alvarez Julian, Bettex Dominique, Bouchez Stefan, Brito Dulce, Černý Vladimir, Comin-Colet Josep, Crespo-Leiro Marisa G., Delgado Juan F., Édes Istvan, Eremenko Alexander A., Farmakis Dimitrios, Fedele Francesco, Fonseca Cândida, Fruhwald Sonja, Girardis Massimo, Guarracino Fabio, Harjola Veli-Pekka, Heringlake Matthias, Herpain Antoine, Heunks Leo M. A., Husebye Trygve, Ivancan Višnja, Karason Kristjan, Kaul Sundeep, Kivikko Matti, Kubica Janek, Masip Josep, Matskeplishvili Simon, Mebazaa Alexandre, Nieminen Markku S., Oliva Fabrizio, Papp Julius-Gyula, Parissis John, Parkhomenko Alexander, Põder Pentti, Pölzl Gerhard, Reinecke Alexander, Ricksten Sven-Erik, Riha Hynek, Rudiger Alain, Sarapohja Toni, Schwinger Robert H. G., Toller Wolfgang, Tritapepe Luigi, Tschöpe Carsten, Wikström Gerhard, von Lewinski Dirk, Vrtovec Bojan, Pollesello Piero

Dátum:

2020

Megjelenés:

Utánközlés / Másodközlés

ISSN:

2057-7540 2057-7559

Megjegyzések:

Levosimendan was first approved for clinic use in 2000, when authorisation was granted by Swedish regulatory authorities for the haemodynamic stabilisation of patients with acutely decompensated chronic heart failure. In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitisation and promotes vasodilatation through the opening of adenosine triphosphate-dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the European Union and Latin America. Areas of clinical application have expanded considerably and now include cardiogenic shock, takotsubo cardiomyopathy, advanced heart failure, right ventricular failure and pulmonary hypertension, cardiac surgery, critical care and emergency medicine. Levosimendan is currently in active clinical evaluation in the US. Levosimendan in IV formulation is being used as a research tool in the exploration of a wide range of cardiac and non-cardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis. To mark the 20 years since the advent of levosimendan in clinical use, 51 experts from 23 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, UK and Ukraine) contributed to this essay, which evaluates one of the relatively few drugs to have been successfully introduced into the acute heart failure arena in recent times and charts a possible development trajectory for the next 20 years.
Papp Zoltán (1965-) (kardiológus, élettanász): Levosimendan Efficacy and Safety : 20 Years of SIMDAX in Clinical Use

Tárgyszavak:

Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk

Megjelenés:

Cardiac Failure Review. - 6 (2020), p. 1-16. -

További szerzők:

Internet cím:

Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat

Lásd még:

Utánközlés (1)

Borító:

Saját polcon:

001-es BibID:	BIBFORM081810
035-os BibID:	(cikkazonosító)1834 (WoS)000502294400077 (Scopus)85091254940 (PMID)31683969
Első szerző:	Pollesello, Piero
Cím:	Short-Term Therapies for Treatment of Acute and Advanced Heart Failure-Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline? / Piero Pollesello, Tuvia Ben Gal, Dominique Bettex, Vladimir Cerny, Josep Comin-Colet, Alexandr A. Eremenko, Dimitrios Farmakis, Francesco Fedele, Cândida Fonseca, Veli-Pekka Harjola, Antoine Herpain, Matthias Heringlake, Leo Heunks, Trygve Husebye, Visnja Ivancan, Kristian Karason, Sundeep Kaul, Jacek Kubica, Alexandre Mebazaa, Henning Mølgaard, John Parissis, Alexander Parkhomenko, Pentti Põder, Gerhard Pölzl, Bojan Vrtovec, Mehmet B. Yilmaz, Zoltan Papp
Dátum:	2019
ISSN:	2077-0383
Megjegyzések:	Both acute and advanced heart failure are an increasing threat in term of survival, quality of life and socio-economical burdens. Paradoxically, the use of successful treatments for chronic heart failure can prolong life but-per definition-causes the rise in age of patients experiencing acute decompensations, since nothing at the moment helps avoiding an acute or final stage in the elderly population. To complicate the picture, acute heart failure syndromes are a collection of symptoms, signs and markers, with different aetiologies and different courses, also due to overlapping morbidities and to the plethora of chronic medications. The palette of cardio- and vasoactive drugs used in the hospitalization phase to stabilize the patient's hemodynamic is scarce and even scarcer is the evidence for the agents commonly used in the practice (e.g. catecholamines). The pipeline in this field is poor and the clinical development chronically unsuccessful. Recent set backs in expected clinical trials for new agents in acute heart failure (AHF) (omecamtiv, serelaxine, ularitide) left a field desolately empty, where only few drugs have been approved for clinical use, for example, levosimendan and nesiritide. In this consensus opinion paper, experts from 26 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, The Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, Turkey, U.K. and Ukraine) analyse the situation in details also by help of artificial intelligence applied to bibliographic searches, try to distil some lesson-learned to avoid that future projects would make the same mistakes as in the past and recommend how to lead a successful development project in this field in dire need of new agents.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk acute heart failure advanced heart failure clinical development levosimendan regulatory clinical trials short-term hemodynamic therapy
Megjelenés:	Journal of Clinical Medicine. - 8 : 11 (2019), p. 1-18. -
További szerzők:	Ben Gal, Tuvia Bettex, Dominique Cerny, Vladimir Comin-Colet, Josep Eremenko, Alexandr A. Farmakis, Dimitrios Fedele, Francesco Fonseca, Candida Harjola, Veli-Pekka Herpain, Antoine Heringlake, Matthias Heunks, Leo Husebye, Trygve Ivancan, Visnja Karason, Kristian Kaul, Sundeep Kubica, Jacek Mebazaa, Alexandre Mølgaard, Henning Parissis, John Parkhomenko, Alexander Põder, Pentti Pölzl, Gerhard Vrtovec, Bojan Yilmaz, Mehmet Birhan Papp Zoltán (1965-) (kardiológus, élettanász)
Internet cím:	DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM114410
035-os BibID:	(scopus)85169671684
Első szerző:	Pölzl, Gerhard
Cím:	Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period : The multinational randomized trial / Pölzl Gerhard, Altenberger Johann, Comín-Colet Josep, Delgado Juan F., Fedele Francesco, Garcia-González Martín Jesús, Gustafsson Finn, Masip Josep, Papp Zoltán, Störk Stefan, Ulmer Hanno, Maier Sarah, Vrtovec Bojan, Wikström Gerhard, Zima Endre, Bauer Axel, LeoDOR Investigators
Dátum:	2023
ISSN:	1388-9842 1879-0844
Megjegyzések:	Aim: The LeoDOR trial explored the efficacy and safety of intermittent levosimendan therapy in the vulnerable phase following a hospitalization for acute heart failure (HF). Methods and results: In this prospective multicentre, double-blind, two-armed trial, patients with advanced HF were randomized 2:1 at the end of an index hospitalization for acute HF to intermittent levosimendan therapy or matching placebo for 12 weeks. All patients had left ventricular ejection fraction (LVEF) ?30% during index hospitalization. Levosimendan was administered according to centre preference either as 6 h infusion at a rate of 0.2 ?g/kg/min every 2 weeks, or as 24 h infusion at a rate of 0.1 ?g/kg/min every 3 weeks. The primary efficacy assessment after 14 weeks was based on a global rank score consisting of three hierarchical groups. Secondary clinical endpoints included the composite risk of tiers 1 and 2 at 14 and 26 weeks, respectively. Due to the COVID-19 pandemic, the planned number of patients could not be recruited. The final modified intention-to-treat analysis included 145 patients (93 in the combined levosimendan arm, 52 in the placebo arm), which reduced the statistical power to detect a 20% risk reduction in the primary endpoint to 60%. Compared with placebo, intermittent levosimendan had no significant effect on the primary endpoint: the mean rank score was 72.55 for the levosimendan group versus 73.81 for the placebo group (p = 0.863). However, there was a signal towards a higher incidence of the individual clinical components of the primary endpoint in the levosimendan group versus the placebo group both after 14 weeks (hazard ratio [HR] 2.94, 95% confidence interval [CI] 1.12-7.68; p = 0.021) and 26 weeks (HR 1.64, 95% CI 0.87-3.11; p = 0.122). Conclusions: Among patients recently hospitalized with HF and reduced LVEF, intermittent levosimendan therapy did not improve post-hospitalization clinical stability.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	European Journal Of Heart Failure. - 25 : 11 (2023), p. 2007-2017. -
További szerzők:	Altenberger, Johann Comin-Colet, Josep Delgado, Juan F. Fedele, Francesco Garcia-González, Martín J. Gustafsson, Finn Masip, Josep Papp Zoltán (1965-) (kardiológus, élettanász) Störk, Stefan Ulmer, Hanno Maier, Sarah Vrtovec, Bojan Wikström, Gerhard Zima Endre (1974-) (kardiológus) Bauer, Axel LeoDOR Investigators
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM090865
Első szerző:	Pölzl, Gerhard
Cím:	Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period / Pölzl Gerhard, Allipour Birgani Shadab, Comín-Colet Josep, Delgado Juan F., Fedele Francesco, Garcia-Gonzáles Martín J., Gustafsson Finn, Masip Josep, Papp Zoltán, Störk Stefan, Ulmer Hanno, Vrtovec Bojan, Wikström Gerhard, Altenberger Johann
Dátum:	2019
ISSN:	2055-5822
Megjegyzések:	Hospitalization for acute heart failure (HF) is associated with a substantial morbidity burden and with associated healthcare costs and an increased mortality risk. However, few if any major medical innovations have been witnessed in this area in recent times. Levosimendan is a first-in-class calcium sensitizer and potassium channel opener indicated for the management of acute HF. Experience in several clinical studies has indicated that administration of intravenous levosimendan in intermittent cycles may reduce hospitalization and mortality rates in patients with advanced HF; however, none of those trials were designed or powered to give conclusive insights into that possibility. This paper describes the rationale and protocol of LeoDOR (levosimendan infusions for patients with advanced chronic heart failure), a randomized, double-blind, placebo-controlled, international, multicentre trial that will explore the efficacy and safety of intermittent levosimendan therapy, in addition to optimized standard therapy, in patients following hospitalization for acute HF. Salient features of LeoDOR include the use of two treatment regimens, in order to evaluate the effects of different schedules and doses of levosimendan during a 12 week treatment phase, and the use of a global rank primary endpoint, in which all patients are ranked across three hierarchical groups ranging from time to death or urgent heart transplantation or implantation of a ventricular assist device to time to rehospitalization and, lastly, time-averaged proportional change in N-terminal pro-brain natriuretic peptide. Secondary endpoints include changes in HF symptoms and functional status at 14 weeks.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	ESC heart failure. - 6 : 1 (2019), p. 174-181. -
További szerzők:	Allipour Birgani, Shadab Comin-Colet, Josep Delgado, Juan F. Fedele, Francesco Garcia-González, Martín J. Gustafsson, Finn Masip, Josep Papp Zoltán (1965-) (kardiológus, élettanász) Störk, Stefan Ulmer, Hanno Vrtovec, Bojan Wikström, Gerhard Altenberger, Johann
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM070106
Első szerző:	Pölzl, Gerhard
Cím:	Repetitive use of levosimendan in advanced heart failure : need for stronger evidence in a field in dire need of a useful therapy / Pölzl Gerhard, Altenberger Johann, Baholli Loant, Beltrán Paola, Borbély Attila, Comin-Colet Josep, Delgado Juan F., Fedele Francesco, Fontana Antonella, Fruhwald Friedrich, Giamouzis Gregory, Giannakoulas George, Garcia-González Martín J., Gustafsson Finn, Kaikkonen Kari, Kivikko Matti, Kubica Jacek, von Lewinski Dirk, Löfman Ida, Malfatto Gabriella, Manito Nicolás, Martínez-Sellés Martin, Masip Josep, Merkely Bela, Morandi Fabrizio, Mølgaard Henning, Oliva Fabrizio, Pantev Emil, Papp Zoltán, Perna Gian Piero, Pfister Roman, Piazza Vito, Bover Ramón, Rangel-Sousa Diego, Recio-Mayoral Alejandro, Reinecke Alexander, Rieth Andreas, Sarapohja Toni, Schmidt Gunter, Seidel Mirko, Störk Stefan, Vrtovec Bojan, Wikström Gerhard, Yerly Patrik, Pollesello Piero
Dátum:	2017
ISSN:	0167-5273
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	International Journal Of Cardiology. - 243 (2017), p. 389-395. -
További szerzők:	Altenberger, Johann Baholli, Loant Beltrán, Paola Borbély Attila (1978-) (kardiológus) Comin-Colet, Josep Delgado, Juan F. Fedele, Francesco Fontana, Antonella Fruhwald, Friedrich Giamouzis, Gregory Giannakoulas, George Garcia-González, Martín J. Gustafsson, Finn Kaikkonen, Kari Kivikko, Matti Kubica, Jacek von Lewinski, Dirk Löfman, Ida Malfatto, Gabriella Manito, Nicolás Martínez-Sellés, Martin Masip, Josep Merkely Béla (1965-) (orvos) Morandi, Fabrizio Mølgaard, Henning Oliva, Fabrizio Pantev, Emil Papp Zoltán (1965-) (kardiológus, élettanász) Perna, Gian Piero Pfister, Roman Piazza, Vito Bover, Ramón Rangel-Sousa, Diego Recio-Mayoral, Alejandro Reinecke, Alexander Rieth, Andreas Sarapohja, Toni Schmidt, Gunter Seidel, Mirko Störk, Stefan Vrtovec, Bojan Wikström, Gerhard Yerly, Patrik Pollesello, Piero
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: